Cargando…

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

Detalles Bibliográficos
Autores principales:	Yan, Wenqiang, Fan, Huishou, Xu, Jingyu, Liu, Jiahui, Li, Lingna, Du, Chenxing, Deng, Shuhui, Sui, Weiwei, Xu, Yan, Zou, Dehui, Qiu, Lugui, An, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344481/ https://www.ncbi.nlm.nih.gov/pubmed/37306432 http://dx.doi.org/10.1097/CM9.0000000000002735

Ejemplares similares

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
por: Xu, Jingyu, et al.
Publicado: (2023)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
por: Jingyu, X., et al.
Publicado: (2022)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
por: Yan, Wenqiang, et al.
Publicado: (2023)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma
por: Yang, Peiyu, et al.
Publicado: (2023)

P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
por: Hagen, Patrick, et al.
Publicado: (2022)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
por: Fan, Huishou, et al.
Publicado: (2023)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population
por: Garrido, David Israel, et al.
Publicado: (2021)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population
por: Udupa, Chethana Babu K, et al.
Publicado: (2020)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
por: Zhong, Ling, et al.
Publicado: (2022)

AMS - ISS
por: Vanden Broeck, Renilde
Publicado: (2019)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Towards Understanding the Origin of Cosmic Ray Electrons with Precision Results from AMS on ISS
por: Xu, Weiwei
Publicado: (2021)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

CALET docked on the ISS
por: Antonella Del Rosso
Publicado: (2015)

P934: THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Tao, Yi, et al.
Publicado: (2023)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_udp5l6ctppmlhbailvav3vpj3c